$CBIS Prop 64 Voting Fuels Cannabis Science to Expand Land Deals Across the Country and Increase Drug Development Programs, Laboratory Extractions, and New Product Releases
Marketwired MarketwiredOctober 31, 2016
Prop 64 Voting Fuels Cannabis Science to Expand Land Deals Across the Country and Increase Drug Development Programs, Laboratory Extractions, and New Product ReleasesView photos
CBIS - Newly Released Product Line Click here for high-resolution version
More
IRVINE, CA--(Marketwired - Oct 31, 2016) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabis-based medicines, is preparing for Prop 64 and a few more states to open as elections approach, bringing a new wave of potential industry changing legislation. The company has laid the foundation for growth with its significant large land development deals to accomplish the goal of increasing its pharmaceutical grade drug output.
Some of the more noteworthy transactions are with unique strategic partners who already have DEA and Department of Agriculture licenses. This will help ensure a quick and risk-averse path to production and thus the ability to increase its drug output for those patients looking for pharmaceutical grade cannabinoid formulations. This upcoming vote is of the utmost importance to any company serving the cannabis industry, and Cannabis Science is continuing to position itself to serve these new markets pending positive voting results.
"We found ourselves at the forefront of a very special opportunity. In preparation, we have been significantly expanding our land portfolio in California and additional states for drug development in order to produce more products and meet demand as it increases. It isn't often in economics when product demand is on the verge of such high growth potential and the anticipated supply is expected to decrease greatly," said, President, CEO, & Co-Founder Raymond C. Dabney, "We are well on our way to increasing our cannabinoid production and getting quality products to market to help meet this demand for all self-medicating patients. We are determined, and thrilled to have this opportunity, to meet these special market needs."
9 More States looking to Vote Yes to Legalizing or Medicinal Usage.
Voters in five states -- California, Arizona, Massachusetts, Maine and Nevada -- will decide whether to fully legalize and regulate marijuana. They would join Washington, Colorado, Alaska and Oregon, states that already allow using marijuana for recreational purposes.
Voters in another four states -- Florida, Montana, North Dakota and Arkansas -- will decide whether to approve marijuana for medical use. They'd join the list of 25 states and the District of Columbia that have approved medical marijuana.
As previously stated, articles have been released stating that cannabis sales in Colorado are slated to exceed alcohol sales only a couple of years' post-legislation. Cannabis Science is headquartered in California, representing one of the largest cannabis markets in the USA. Just how big would legalizing marijuana be in California? Well, it's the most populous state in the US and has the world's sixth-largest economy with a gross domestic product of about $2.5 trillion. In California's much larger market, this type of consumer support in the cannabis industry has huge potential to drive Cannabis Science's bottom line.
"We feel we are ready to meet the demands of more patients than ever before, and the timing couldn't be better, with the tremendous support for Proposition 64 and other pro-cannabis initiatives across the nation. We are pushing very hard and very fast to become one of the largest land procurement companies for medical cannabis drug development. We are rapidly and successfully expanding our national land targets in California, Nevada, Colorado, Washington and heading East next. Additionally, we are negotiating more deals with distribution networks and new dispensaries across the state of California and setting up for Nevada and a few more states to reach many more patients in need of cannabinoid formulations. The company's most recent new products, including a pain relief product, an immune system bolster, and a sleep aid, are very accessible, even to first-time legal self-medicating patients. Presently Cannabis Science is in negotiation for a land plot that is currently in production and will give us a large amount of inventory for drug development and future medicinal products," concludes, Mr. Dabney.
